Clinical Trials Arena January 14, 2026
Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 vaccines.
BioNTech aims to have multiple commercialised cancer drugs by 2030 as the company continues its pivot away from Covid-19 vaccines.
Speaking at the J.P. Morgan Healthcare Conference in San Francisco, taking place from 12 to 15 January, BioNTech CEO Ugur Sahin said: “Our ambition is to build a fully integrated multiproduct oncology company, and 2026 is just the beginning of our road map.”
BioNTech became a well-established company in the pharmaceutical sector after co-developing the first mRNA Covid-19 vaccine with Pfizer. Amid waning demand for Covid-19 products, however, BioNTech’s share price is currently trading around 77% lower compared to...
Today's Sponsors
Today's Sponsor